Neoplasms, Plasma Cell: all 2,314 studies
Page 10 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT06232707Phase 3
- Selinexor, Cyclophosphamide and Prednisone in MyelomaCompletedNCT06212596Phase 2
- Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMMActive, not recruitingNCT06205823
- Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple MyelomaCompletedNCT06170151
- Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory DrugsCompletedNCT06160167
- Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene VicleucelActive, not recruitingNCT06154902
- A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple MyelomaCompletedNCT06151717
- Study of BEBT-908 in Subjects With Advanced Hematological TumorsCompletedNCT06082596Phase 1
- Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnNCT06050512Phase 1/2
- Alvocade® (Bortezomib) Safety and Effectiveness StudyCompletedNCT06012383
- An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple MyelomaWithdrawnNCT05980507Phase 1
- Providing Cancer Care Closer to Home for Patients With Multiple MyelomaTerminatedNCT05971056Not applicable
- CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT05950113Phase 1
- Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCTCompletedNCT05928156Not applicable
- mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT05918250Phase 1
- Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT05908396Phase 1
- A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedNCT05896774Phase 1
- Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple MyelomaActive, not recruitingNCT05889221Not applicable
- Corneal Toxicity in Patients Treated by Belantamab MafodotinCompletedNCT05887206
- Study of CT071 Injection in RRMM or PPCLActive, not recruitingNCT05838131Early Phase 1
- Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplantWithdrawnNCT05820763Phase 2
- The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma PatientsStatus unknownNCT05802992Phase 3
- Optical Genome Mapping in Characterization of Multiple MyelomaCompletedNCT05786105
- Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell ImmunotherapyCompletedNCT05763563Not applicable
- AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple MyelomaStatus unknownNCT05740891Phase 1
- Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple MyelomaCompletedNCT05724966
- The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based MetabolomicsStatus unknownNCT05718401
- Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma ProgressionCompletedNCT05712967
- A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple MyelomaStatus unknownNCT05712083Phase 2
- Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow TransplantationActive, not recruitingNCT05697913Not applicable
- Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple MyelomaStatus unknownNCT05693012
- Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT05673967
- Clinical Study of the Safety and Efficacy of BCMA CAR-NKStatus unknownNCT05652530Early Phase 1
- Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell DiseasesWithdrawnNCT05647512Phase 1/2
- A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)TerminatedNCT05641324Phase 1
- Non-invasive MRD Assessment in Multiple MyelomaCompletedNCT05625971
- Understanding Patterns of Fatigue in Health and DiseaseCompletedNCT05622669
- A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple MyelomaCompletedNCT05620420
- Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative StudyCompletedNCT05555329Phase 4
- Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaStatus unknownNCT05549973Phase 1
- Benefits of Adapted Physical Activity for Chronic Osteoarticular Pain in Patients With Multiple MyelomaStatus unknownNCT05548686Not applicable
- Thrombosis in Patients With Multiple Myeloma in an University Medical CenterCompletedNCT05541978
- Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple MyelomaStatus unknownNCT05536700
- Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid MalignanciesWithdrawnNCT05513612Phase 1
- Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and DexamethasoneStatus unknownNCT05509374Phase 2
- Long-term KRd in Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05495620
- Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCTActive, not recruitingNCT05493800Phase 2
- Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.WithdrawnNCT05493618Phase 1/2
- This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.Status unknownNCT05486975Early Phase 1
- Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma PatientsApproved for marketingNCT05463939
- Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple MyelomaNo longer availableNCT05462639
- A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple MyelomaStatus unknownNCT05448404Not applicable
- Assessing the Impact of a Financial Navigation Program for Patients With Multiple MyelomaCompletedNCT05448196Not applicable
- Serum NGAL IN Patients With Multiple MyelomaStatus unknownNCT05439538
- Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MMStatus unknownNCT05438394Phase 1
- Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) PatientsCompletedNCT05428163
- Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple MyelomaTerminatedNCT05427812Phase 1/2
- Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple MyelomaStatus unknownNCT05412329Phase 1
- Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMMWithdrawnNCT05408026Phase 1/2
- Patient With MMRR Treated With Belantamab Mafotidine on MonotherapyCompletedNCT05393024
- Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body ScannerStatus unknownNCT05381077Not applicable
- 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple MyelomaStatus unknownNCT05364177Early Phase 1
- Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell TherapyWithdrawnNCT05362331Not applicable
- Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT05346198Phase 1
- Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After AutotransplantCompletedNCT05338047Phase 2
- Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple MyelomaActive, not recruitingNCT05336383Phase 2
- The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple MyelomaStatus unknownNCT05331313
- A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple MyelomaStatus unknownNCT05325801Phase 1
- Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.WithdrawnNCT05321862Phase 2
- Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05308225Phase 1/2
- To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MMActive, not recruitingNCT05302648Early Phase 1
- Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.Status unknownNCT05297240
- Study of Novel Regimens in Relapsed or Refractory Multiple MyelomaTerminatedNCT05289492Phase 1
- Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)CompletedNCT05284591
- Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)TerminatedNCT05276622
- Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#Status unknownNCT05266768Phase 1
- Plasma-free Replacement in Patients With Multiple MyelomaCompletedNCT05251896Not applicable
- A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT05243342Phase 1
- A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Phase 3
- Study of ORIC-533 in Relapsed or Refractory Multiple MyelomaCompletedNCT05227144Phase 1
- A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class ExposureCompletedNCT05217082
- Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell TherapyWithdrawnNCT05204160Phase 2
- A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple MyelomaStatus unknownNCT05201118Phase 1
- Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of CarfilzomibStatus unknownNCT05184595Not applicable
- A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWithdrawnNCT05183139Phase 4
- FT576 in Subjects With Multiple MyelomaCompletedNCT05182073Phase 1
- Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple MyelomaWithdrawnNCT05170789Phase 2
- B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05150522Phase 1/2
- A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
- Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma SurvivorsCompletedNCT05142371Not applicable
- Survival Outcomes of Multiple Myeloma Patients Admitted on Assiut Clinical Hematology UnitStatus unknownNCT05119205
- Descartes-25 in Relapsed/Refractory Multiple MyelomaTerminatedNCT05113342Phase 1
- Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological MalignancyCompletedNCT05101759Not applicable
- A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MMStatus unknownNCT05088330Not applicable
- Stem Cell Translpantation in Multiple MyelomaCompletedNCT05082675Phase 2
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Phase 1/2
- A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05066022Not applicable
- Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedNCT05065866Phase 1
- Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMStatus unknownNCT05052970Phase 1
- Marizomib Central Nervous System (CNS)WithdrawnNCT05050305Phase 2